Pituitary Tumor Transforming Gene Causes Aneuploidy and p53-dependent and p53-independent Apoptosis*

The pituitary tumor transforming gene, PTTG, is abundantly expressed in several neoplasms. We recently showed that PTTG overexpression is associated with apoptosis and therefore have now studied the role of p53 in this process. In MCF-7 breast cancer cells that express wild type p53, PTTG overexpression caused apoptosis. p53 was translocated to the nuclei in cells expressing PTTG. Overexpression of p53, along with PTTG, augmented apoptosis, whereas expression of the human papillomavirus E6 protein inhibited PTTG-induced apoptosis. In MG-63 osteosarcoma cells that are deficient in p53, PTTG caused cell cycle arrest and subsequent apoptosis that was inhibited by caspase inhibitors. A proteasome inhibitor augmented PTTG expression in stable PTTG transfectants, suggesting that down-regulated PTTG expression is required for cell survival. Finally, MG-63 cells expressing PTTG showed signs of aneuploidy including the presence of micronuclei and multiple nuclei. These results indicate that PTTG overexpression causes p53-dependent and p53-independent apoptosis. In the absence of p53, PTTG causes aneuploidy. These results may provide a mechanism for PTTG-induced tumorigenesis whereby PTTG mediates aneuploidy and subsequent cell transformation.

[1]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[2]  S. Melmed,et al.  Pituitary Tumor Transforming Gene (PTTG) Transforming and Transactivation Activity* , 2000, The Journal of Biological Chemistry.

[3]  L. Cole,et al.  False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations , 2000, The Lancet.

[4]  Jiandong Chen,et al.  Nuclear exclusion of p53 in a subset of tumors requires MDM2 function , 2000, Oncogene.

[5]  T. Okamoto,et al.  Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. , 1999, Cancer research.

[6]  S. Melmed,et al.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.

[7]  J. Ludlow,et al.  Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. , 1999, Experimental cell research.

[8]  M. Kirschner,et al.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. , 1999, Science.

[9]  S. Kakar,et al.  Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis , 1999, Cytogenetic and Genome Research.

[10]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Prochownik,et al.  C-myc overexpression and p53 loss cooperate to promote genomic instability , 1999, Oncogene.

[12]  F. Ramos-Morales,et al.  hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG , 1998, Oncogene.

[13]  K. Pienta,et al.  Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. , 1998, Cancer research.

[14]  M. Serrano,et al.  p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.

[15]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[16]  V. D’Agati,et al.  C-MYC–induced Apoptosis in Polycystic Kidney Disease Is Bcl-2 and p53 Independent , 1997, The Journal of experimental medicine.

[17]  S. Hilsenbeck,et al.  Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53 , 1997, Molecular and cellular biology.

[18]  G. Prendergast,et al.  c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. , 1995, Oncogene.

[19]  S. de Vos,et al.  20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. , 1995, Cancer research.

[20]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[21]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[22]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[23]  N. Chandar,et al.  Inactivation of p53 gene in human and murine osteosarcoma cells. , 1992, British Journal of Cancer.

[24]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.